The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also mentions a new hair transplant therapy approved by the government.
The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
A 17-year-old has been using topical minoxidil and finasteride for hair loss but is advised by a dermatologist to taper off due to age concerns. Other users suggest continuing minoxidil but stopping finasteride until at least 18, and consulting a specialized pediatric dermatologist.
Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.
The conclusion of the conversation is that the user regrets not starting finasteride earlier to treat their hair loss. They are currently using dutasteride, oral minoxidil, and RU58841. Other users in the conversation express frustration with fearmongering about finasteride and emphasize the benefits of starting treatment early.
Oral minoxidil is effective for hair loss but can cause cardiovascular side effects, such as pericardial effusion, especially in those with genetic predispositions. Starting with low doses and monitoring cardiovascular health are advised to reduce risks.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
The conversation is about hair loss treatments, specifically discussing the use of dutasteride, minoxidil, and the potential benefits of a DNA test and PRP therapy. Opinions vary, with some users skeptical about the DNA test and PRP, suggesting sticking with current treatments.
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
A 27-year-old man's experience with taking Finasteride to treat hair loss and the positive side effects he has experienced, such as improved skin. The user also shared their journey of how they were scared away from taking Finasteride due to fear of possible side effects before eventually deciding to take it.
The potential health risks associated with long-term use of finasteride and dutasteride, with some responses pointing out the low quality of the journal that published the review article as well as highlighting other alternatives such as keto or minoxidil, and RU58841.
A user visited a dermatologist for hair loss concerns and was prescribed a hair lotion called "Lotion revolotion evdermia," which is meant for hair toning, hydration, and anti-aging, not regrowth. The user found the dermatologist's behavior and the prescription to be questionable.
The user experienced hair thinning and was diagnosed with alopecia incognito and male pattern baldness. They are using minoxidil, finasteride, and dutasteride scalp injections, reporting gradual improvement with no side effects.
The conversation is about a user planning to undergo a hair transplant and seeking information on clinics that perform Verteporfin treatment. A user suggests Dr. Barghouthi might offer this service.
A 26-year-old user shared their 3-month progress using oral finasteride and oral minoxidil for hair loss. They experienced side effects like reduced libido and brain fog at higher doses and adjusted their dosage to manage these effects.
A double blind, placebo-controlled study that looked into the potential effectiveness of topical fluridil for treating male androgenetic alopecia, showing increased anagen to telogen ratios with no reported side effects on libido or sexual performance.
The conversation is about the lack of discussion on Low-level laser light therapy (LLLT) laser caps for hair loss. One user questions their effectiveness, and another asserts they don't work.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.
A 25-year-old from Italy is experiencing hair thinning and seeks advice on obtaining finasteride, which requires a prescription in Italy. Suggestions include consulting a local doctor or using telehealth services.
Pyrilutamide 0.9% (kx-826) is available for shipping to Europe from Amazon US and Koshinemall. Shipping costs and availability vary between the two shops.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
The conversation concludes that finasteride, a 5α-Reductase inhibitor used for hair loss, does not impair cognition either short-term or long-term. It suggests "brain fog" is not caused by the medication.
A user is considering starting finasteride for hair thinning but is concerned about side effects like low libido and gynecomastia. They plan to consult a dermatologist and are advised to test DHT, testosterone, and estradiol levels.
The conversation discusses why there are no FDA-approved NSAAs like RU58841 on the market, despite their potential superiority to 5AR inhibitors like finasteride. It explores the effectiveness of treatments like Minoxidil, finasteride, and RU58841 for hair loss.